Munich, Germany – 5th December 2023 – Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the appointment of Dr. Matthias Hebben as its Chief Technology Officer, effective immediately. Dr. Hebben brings with him substantial experience in process development for manufacturing of gene therapies, development of analytical methods and preclinical studies for drug development.
Dr. Hebben joins CTx from Alexion Pharmaceuticals Inc., where he held the position of VP of Pipeline and Technology Development. Prior to that, he was Global Vice President of Technology Development at LogicBio Therapeutics and Director of Gene Therapy Technology and CMC Development at Genethon where he led the development of manufacturing processes for AAV and lentivirus vectors as well as innovative technologies for AAV production improvement.
“We are delighted to welcome Matthias to the CTx team as CTO,” said Dr Rafiq Hasan, Chief Executive Officer. “Matthias’ deep expertise and experience in gene therapy and process development will be invaluable as we continue to develop innovative medicines, particularly CTx001, a gene therapy for the treatment of Geographic Atrophy secondary to AMD. We are excited to have him on board to further our mission of developing the next generation of medicines for complement-mediated diseases.”
Dr. Hebben received his biotechnology engineering degree at the Ecole Supérieure de Biotechnologies de Strasbourg (ESBS) prior to receiving his doctorate degree in Molecular Biology at the Université Côte d’Azur.
“I am thrilled to join the CTx team and contribute to the development of their innovative therapies,” said Dr Matthias Hebben, Chief Technology Officer. “I am looking forward to working with this team of experts and implement strong manufacturing technologies to support the product development across all pipeline assets.”
About Complement Therapeutics GmbH:
Complement Therapeutics GmbH (CTx) is a German headquartered early-stage biotechnology company focused on the research and development of novel therapeutics for complement- mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade.
Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for GA, a leading cause of blindness. Additional programs will evaluate potential therapeutic opportunities in other complement-mediated conditions.
The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable the quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.
The Company has subsidiaries in the UK (Complement Therapeutics Ltd) and in the USA (Complement Therapeutics Inc) as well as research laboratories in Stevenage, UK.
For more information please visit: https://complementtx.com/
Dr Rafiq Hasan, CEO and Managing Director
Complement Therapeutics GmbH